V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10005157 | 10003224 | null | 79.3 | Palliative (P) | 2018-11-19 | 2018-11-22 | VINCRISTINE | N | N | 10274223 | CAPECITABINE + CARBOPLATIN |
| 10005158 | 10003224 | null | null | Palliative (P) | 2018-01-31 | 2018-02-27 | Ofatumumab Monthly | null | N | 10274223 | CAPECITABINE + CARBOPLATIN |
| 10005159 | 10003224 | 1.84 | 102 | Palliative (P) | 2018-05-27 | 2018-05-28 | R CODOX M | 2 | N | 10274223 | AML16 TRIAL |
| 10005160 | 10008868 | 1.62 | 0 | Not known (9) | 2017-02-03 | 2017-02-07 | Trastuzumab 21 day loading dose | 2 | N | 10280634 | CAPECITABINE + CARBOPLATIN |
| 10005161 | 10003225 | 1.85 | 81.8 | Palliative (P) | 2017-02-14 | 2017-02-22 | FCR Oral - Cycle 1 | 02 | Y | 10282243 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 10005162 | 10003226 | 1.77 | 84.25 | Palliative (P) | 2017-05-18 | 2017-05-18 | Fluorouracil + Folinic + RT Bossett | 02 | N | 10282430 | IBRUTINIB |
| 10005163 | 10003226 | 0 | 83.5 | Adjuvant (A) | 2018-12-01 | 2018-12-04 | INCA TRIAL | N | N | 10282430 | MPV |
| 10005164 | 10003227 | 1.67 | 116 | Neo-adjuvant (N) | 2015-02-23 | 2015-03-03 | AML18 PILOT TRIAL | N | N | 10283234 | NEPTUNE TRIAL |
| 10005165 | 10006809 | 1.66 | 70.6 | Disease modification (D) | 2017-08-08 | 2017-08-12 | Vinblastine | Y | N | 10283669 | RUXOLITINIB |
| 10005166 | 10006809 | 1.82 | null | Neo-adjuvant (N) | 2017-07-22 | 2017-07-24 | Sorafenib | 01 | null | 10283669 | GEFITINIB |
| 10005167 | 10003228 | 1.58 | 56 | null | null | 2018-12-09 | VINORELBINE | 02 | null | 10284364 | CAP + RT |
| 10005168 | 10003229 | 1.8 | 76 | Adjuvant (A) | 2018-03-25 | 2018-03-25 | CMV | 2 | N | 10285179 | CISPLATIN + FLUOROURACIL + RT |
| 10005169 | 10003230 | 1.73 | null | null | 2018-03-15 | 2018-03-15 | Vemurafenib | 01 | N | 10285374 | VEMURAFENIB |
| 10005170 | 10003230 | 1.7 | 70.6 | Palliative (P) | 2018-04-25 | 2018-04-25 | Cisplatin +Fluorouracil (3 wk) | Y | N | 10285374 | CHLORAMBUCIL + RITUXIMAB |
| 10005171 | 10003231 | null | null | Curative (C) | 2019-11-01 | 2019-11-24 | INCA TRIAL | N | Y | 10286675 | PACLITAXEL + TRASTUZUMAB |
| 10005172 | 10003232 | 1.68 | 67.3 | Palliative (P) | 2017-04-28 | 2017-05-05 | CHLVPP | N | N | 10288922 | PAZOPANIB |
| 10005173 | 10003233 | 1.53 | null | Palliative (P) | 2018-07-07 | 2018-08-20 | DABRAFENIB | 02 | N | 10289061 | TRASTUZUMAB |
| 10005174 | 10003233 | 1.68 | 70.6 | Disease modification (D) | 2018-01-07 | 2018-01-11 | CISPLATIN + FLUOROURACIL | 02 | N | 10289061 | CYTARABINE |
| 10005175 | 10003233 | 1.67 | 75 | Disease modification (D) | 2017-02-02 | 2017-02-07 | Fluorouracil + Folinic + RT Bossett | 02 | N | 10289061 | IPILIMUMAB + NIVOLUMAB |
| 10005176 | 10003233 | 1.63 | 56.6 | Curative (C) | 2018-12-15 | 2018-12-16 | EC + DOCETAXEL | 02 | N | 10289061 | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN |
| 10005177 | 10003234 | null | 67 | null | 2017-06-16 | 2017-06-23 | CARBOPLATIN + PACLITAXEL + RT | Y | N | 10290467 | TCH |
| 10005178 | 10003235 | null | 86.4 | Palliative (P) | null | 2018-03-12 | Gemcitabine+Paclitaxel (Neo-tAnGo) | N | null | 10291060 | DABRAFENIB + TRAMETINIB |
| 10005179 | 10003235 | 1.64 | 80.7 | Curative (C) | 2015-06-30 | 2015-07-16 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | 10291060 | IPILIMUMAB |
| 10005180 | 10003236 | 1.67 | 91.6 | Palliative (P) | 2017-03-12 | 2017-03-16 | DABRAFENIB + TRAMETINIB | 2 | N | 10307114 | MPT |
| 10005181 | 10003236 | 0 | null | Curative (C) | 2017-10-04 | 2017-10-09 | AML 19 TRIAL | 01 | Y | 10307114 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10005182 | 10008266 | 0 | 79.8 | Palliative (P) | 2017-02-09 | 2017-02-09 | Pazopanib | 02 | N | 10312881 | CISPLATIN + VINORELBINE + RT |
| 10005183 | 10003237 | 1.7 | 0 | Palliative (P) | 2015-04-17 | 2015-04-17 | CETUXIMAB | N | N | 10316497 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB |
| 10005184 | 10003237 | 1.63 | 102 | Palliative (P) | 2017-09-06 | 2017-09-11 | CETUXIMAB + IRINOTECAN + MDG | N | N | 10316497 | TEMOZOLOMIDE |
| 10005185 | 10008267 | 1.64 | null | Palliative (P) | 2015-10-31 | 2015-11-04 | CAPECITABINE + CISPLATIN + Trastuzumab | Y | null | 10320483 | CETUXIMAB + IRINOTECAN + MDG |
| 10005186 | 10003238 | 1.8 | 53 | null | 2017-03-29 | 2017-03-29 | Sorafenib | N | N | 10322816 | DOXORUBICIN + OLARATUMAB |
| 10005187 | 10003238 | 0 | 76.9 | Curative (C) | null | 2016-12-12 | CARFILZOMIB | 02 | N | 10322816 | STAMPEDE TRIAL |
| 10005188 | 10003238 | 0 | 57.1 | Palliative (P) | 2018-01-20 | 2018-01-26 | TRASTUZUMAB | N | N | 10322816 | BEVACIZUMAB |
| 10005189 | 10003239 | 1.48 | 55 | null | 2019-01-29 | 2019-01-29 | DOCETAXEL + TRASTUZUMAB | N | N | 10330137 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 10005190 | 10003240 | null | 73.4 | Palliative (P) | 2019-04-19 | 2019-04-19 | MPV (cycle 1-4) | N | N | 10330768 | HCX |
| 10005191 | 10003241 | 1.75 | 80.8 | Palliative (P) | null | 2015-07-09 | Capecitabine + Mitomycin | N | Y | 10331133 | CARBOPLATIN + PACLITAXEL + RT |
| 10005192 | 10003242 | 1.76 | null | Palliative (P) | 2019-08-09 | 2019-08-28 | CETUXIMAB + IRINOTECAN + MDG | Y | N | 10331847 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10005193 | 10003243 | 1.57 | 65.5 | Disease modification (D) | 2018-05-10 | 2018-05-23 | Mitomycin Intravesical | N | N | 10331857 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 10005194 | 10003244 | null | 64 | Palliative (P) | 2019-02-11 | 2019-02-21 | Dacarbazine | N | N | 10334104 | CISPLATIN + FLUOROURACIL + RT |
| 10005195 | 10003245 | 1.72 | 62.1 | Palliative (P) | 2019-05-12 | 2019-05-14 | EOF | 01 | N | 10334546 | LOMUSTINE |
| 10005196 | 10003246 | 0 | 77.4 | Palliative (P) | null | 2016-05-08 | Cisplatin + Fluorouracil + RT 5day | N | N | 10335155 | SUNITINIB |
| 10005197 | 10006816 | null | 72.5 | Palliative (P) | 2016-02-07 | 2016-03-02 | MYELOMA XI TRIAL | N | N | 10335267 | TAC + TRASTUZUMAB |
| 10005198 | 10003247 | 1.68 | null | null | 2018-03-12 | 2018-03-13 | IBRUTINIB | N | N | 10335666 | GEFITINIB |
| 10005199 | 10003248 | 1.83 | 67.8 | Palliative (P) | 2014-06-07 | 2014-07-08 | Bevacizumab 5mg/kg | N | N | 10336154 | CYTARABINE |
| 10005200 | 10003248 | 1.77 | 56.7 | Palliative (P) | 2018-06-16 | 2018-06-25 | Bevacizumab + CARBOPLATIN + PACLITAXEL | N | N | 10336154 | PAZOPANIB |
| 10005201 | 10003249 | 1.72 | 0 | Palliative (P) | 2019-01-08 | 2019-02-04 | Bexarotene | N | N | 10336299 | DABRAFENIB + TRAMETINIB |
| 10005202 | 10003250 | 1.68 | 67.8 | Palliative (P) | 2017-12-19 | 2017-12-21 | CISPLATIN + FLUOROURACIL | N | N | 10336923 | AML17 TRIAL |
| 10005203 | 10003251 | 1.76 | 114 | Adjuvant (A) | 2015-06-11 | 2015-06-15 | Cisplatin + Docetaxel +Fluorouracil | 02 | N | 10337374 | GEFITINIB |
| 10005204 | 10003252 | 1.69 | 64 | Curative (C) | 2016-03-19 | 2016-03-30 | CISPLATIN + FLUOROURACIL | 02 | N | 10337376 | MITOMYCIN INTRAVESICULAR |
| 10005205 | 10003252 | 1.74 | 102.3 | Palliative (P) | 2018-03-04 | 2018-03-08 | CETUXIMAB + RT | N | N | 10337376 | DABRAFENIB |
| 10005206 | 10008268 | null | 66.9 | Curative (C) | 2016-12-06 | 2016-12-06 | CISPLATIN + VINORELBINE + RT | 2 | N | 10338234 | CISPLATIN + GEMCITABINE + RITUXIMAB |